Neuromuscular Blockade (NMB) in ARDS

Neuromuscular blocking agents (NMBAs) are sometimes used in patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) to improve oxygenation, reduce ventilator dyssynchrony, and facilitate lung-protective ventilation. When used early and selectively, short-term NMB can reduce lung injury caused by high tidal volumes and excessive patient effort. However, due to potential risks such as ICU-acquired weakness, their use should be limited, targeted, and closely monitored.

1.  Drug Selection & Dosing

A. Cisatracurium (Preferred)

Mechanism of Action

• Cisatracurium is a non-depolarizing neuromuscular blocking agent from the benzylisoquinolinium class.
• It works by competitively inhibiting acetylcholine at the neuromuscular junction, leading to skeletal muscle relaxation without causing muscle depolarization.

Advantages

• Organ-independent metabolism:
  • Metabolized via Hofmann elimination, a temperature- and pH-dependent process.
  • This makes it ideal for critically ill patients with hepatic or renal dysfunction, as it does not rely on organ clearance.
• Predictable offset:
  • Does not accumulate with prolonged use.
  • Minimal risk of prolonged neuromuscular blockade after stopping the infusion, especially when used for ≤48 hours.

Dosing Guidelines

• Bolus dose:
  • 0.15–0.2 mg/kg IV — used to initiate paralysis quickly.
• Continuous infusion:
  • Start at 0.5–5 mcg/kg/min.
  • Titrate to effect, aiming for 1–2 out of 4 twitches on the Train-of-Four (TOF) monitoring — a standard method for assessing the depth of neuromuscular blockade.

 

B. Rocuronium (Alternative)

• Rocuronium is a non-depolarizing aminosteroid NMBA, used when cisatracurium is unavailable.
• It provides effective muscle paralysis for mechanical ventilation, particularly in patients with severe ARDS or during rapid sequence intubation.

Dose

• Bolus Dose:
  • 0.6–1.2 mg/kg IV — rapid onset (~1–2 minutes), often used for intubation or acute control.
• Continuous Infusion:
  • 5–10 mcg/kg/min, titrated based on Train-of-Four (TOF) monitoring to achieve adequate paralysis (1–2 twitches out of 4).

Caution

• Metabolism:
  • Rocuronium is primarily metabolized and excreted by the liver and kidneys.
• In patients with hepatic or renal impairment, clearance may be delayed, leading to a prolonged duration of action and increased risk of accumulated paralysis after discontinuation.
• Always monitor closely and consider dose reduction or extended TOF monitoring in these patients.

3. Monitoring & Safety

A. Depth of Paralysis (TOF Monitoring)

• Goal: 1–2/4 twitches (avoid complete blockade).
• Assess q4–6h (clinical exam + TOF).

B. Sedation & Analgesia Requirements

• Must be deeply sedated (RASS -4 to -5) before NMB.
  • Propofol + opioid (fentanyl) typically required.
• No sedation without NMB (patient may be awake but paralyzed!).

C. Adverse Effects & Mitigation

Complication	Prevention/Management
Critical illness myopathy	Minimize duration (<48 hrs), early mobility post-NMB.
Ventilator-associated pneumonia (VAP)	Strict oral care, HOB elevation.
Prolonged paralysis	Avoid steroids + NMB, use cisatracurium.

4. Ventilator Synchronization

Effective synchronization between the ventilator and the patient is critical in ARDS to ensure lung-protective ventilation, minimize ventilator-induced lung injury (VILI), and promote oxygenation. When neuromuscular blocking agents are used, the ventilator settings must be carefully adjusted to maintain lung-protective goals.

1. Ventilator Mode

• Pressure-Controlled Ventilation (PCV) or Pressure-Regulated Volume Control (PRVC) are preferred.
  • PCV ensures a constant pressure during inspiration, minimizing barotrauma.
  • PRVC adapts to patient lung mechanics by adjusting pressure to deliver a target tidal volume.
  • Both modes provide better control in paralyzed patients and reduce ventilator-patient dyssynchrony.

 

2. Key Ventilator Settings

• Tidal Volume (V_T):
  • Set at 4–6 mL/kg of Predicted Body Weight (PBW) to minimize volutrauma.
  • This low-volume strategy is proven to reduce mortality in ARDS (ARDSNet protocol).
• Plateau Pressure (P_plat):
  • Must be kept <30 cmH₂O to avoid alveolar overdistension and barotrauma.
• PEEP (Positive End-Expiratory Pressure):
  • Use ≥10–15 cmH₂O to prevent alveolar collapse (atelectasis) and improve oxygenation by recruiting underinflated lung units.
  • High PEEP is especially helpful in moderate to severe ARDS.

 

3. I:E Ratio (Inspiratory:Expiratory)

• Typical settings: 1:1 to 1:2.
• Adjust to prolong expiration if auto-PEEP (intrinsic PEEP due to incomplete exhalation) is suspected.
  • Auto-PEEP can lead to breath stacking, increased intrathoracic pressure, and hemodynamic compromise.
  • Clues include high peak pressures with normal plateau pressures and hypotension.

 

5. Weaning NMB (Neuro Muscular Blockade) 

After 48 hours of neuromuscular blockade typically used to improve ventilator synchrony and oxygenation in severe ARDS timely weaning is essential to prevent complications such as prolonged paralysis or ICU-acquired weakness.

 

1. Discontinue Infusion After 48 Hours

• NMBAs like cisatracurium are usually limited to 48 hours of use to:
  • Avoid prolonged muscle paralysis.
  • Reduce the risk of ICU-acquired weakness.
• After 48 hours, evaluate:
  • Oxygenation status (PaO₂/FiO₂ ratio).
  • Lung compliance and ventilator synchrony.
  • If oxygenation has improved and sedation is adequate, begin weaning.

2. Resume Spontaneous Breathing

• Follow the SAT/SBT (Spontaneous Awakening Trial / Spontaneous Breathing Trial) protocol:
  • Stop sedation and allow the patient to awaken.
  • Assess for readiness to initiate spontaneous breathing.
  • Perform an SBT (e.g., T-piece trial or pressure support ventilation) to test the ability to breathe without full ventilator support.

3. Monitor for Neuromuscular Weakness

• Prolonged NMB use or critical illness itself can result in ICU-acquired weakness, including:
  • Critical illness polyneuropathy (CIP).
  • Critical illness myopathy (CIM).
• Screening Tools:
  • MRC (Medical Research Council) Score:
    • Measures strength in 6 muscle groups (max score = 60).
    • A total score <48 indicates significant weakness.
  • Clinical signs: generalized weakness, delayed ventilator weaning, or flaccid limbs.